Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cisbio Bioassays Launches Epigenetics Toolbox

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Pioneer of HTRF® technology expands platform to address growing field of epigenetics therapeutic research.

Cisbio Bioassays has announced the launch of its epigenetics toolbox for use in drug discovery research.

Epigenetics is a crucial field of study for the pharmaceutical and biotechnology industries due to its large range of applications related to human health.

This epigenetics toolbox, which offers a robust and reliable resource for such studies and is based on HTRF® technology, was introduced in Europe at MipTec 2012 in Basel, Switzerland and will be released on October 1st in the United States at Discovery on Target 2012 in Boston, Massachusetts.

Cisbio Bioassays’ epigenetics toolbox is a selection of conjugates specifically developed by the company for epigenetics studies, in response to requests from pharmaceutical and biotechnology researchers for reagents that would help better understand how these events occur through epigenetic mechanisms and how they relate to multiple therapeutic areas and diseases such as metabolic, CNS and immune system disorders.

The toolbox works in combination with Cisbio Bioassays’ other HTRF-based reagents to provide a single, robust and easy-to-use technology for studying classes such as histone methylation and histone demethylation.

“Protein: protein interactions and modifications have long been front and center in drug discovery research and now epigenetics target classes have become highly sought after by researchers because of their broad span of applications,” said François Degorce, head of marketing and communications at Cisbio Bioassays.

Degorce continued, “Epigenetics has become one of Cisbio Bioassays’ core research programs in response to the high demand from clients for more specific study tools, like HTRF, that can be applied to this field. To meet this need, we will regularly implement new assays that allow for studying relevant enzymes and the way in which they function. In fact, our development of this first set of reagents parallels our global commitment to introducing novel tools to our growing catalogue, much as we have been doing with our kinase screening platform throughout the year.”

As part of the development of its kinase screening platform, Cisbio Bioassays has also launched two HTRF cellular kinase assays, Phospho-MEK1 and Phospho-MEK1/2.

These assays, designed for detecting and studying activated MEK when phosphorylated at Ser218 and 222 directly in whole cells, can be used for the investigation of the MAP kinase pathway and therefore the screening of potential anti-cancer therapeutic compounds.

Cisbio’s kinase screening platform now comprises 11 assays - Phospho-CREB (Ser133), Phospho-mTOR (Ser2448) and Phospho-EGFR were introduced in June 2012 - and additional kits are planned in the upcoming months.

All assays feature the benefits of HTRF technology: streamlined protocols, miniaturization and application to any phase of drug screening.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cisbio Bioassays and IGF Launch CNS Drug Discovery Research Program
Cisbio Bioassays, member of IBA Group and global provider of HTRF® (homogenous time resolved fluorescence) technology and services to facilitate drug discovery, has announced the launch of the GluSense research and development program in partnership with the Functional Genomics Institute of Montpellier, France.
Tuesday, November 30, 2010
Scientific News
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
UC San Diego Team Up with Illumina to Speed-Read Your Microbiome
Data analysis app accelerates studies aimed at using microbes to predict, diagnose and treat human diseases.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos